G.CLIPS biotech’s Post

A new option for synovial sarcoma!

#Lungcancer #ASCO #HiRO #Taletrectinib Great data Efficacy and Safety of Taletrectinib in Chinese Patients With #ROS1+ #Non–Small Cell Lung Cancer: The Phase II #TRUST-I Study

Longitude portfolio company Opna Bio has dosed its first patient with OPN-6602, a potent and selective EP300/CBP bromodomain inhibitor, in a Phase 1 clinical study in multiple myeloma. Multiple myeloma is a type of blood cancer derived from malignant plasma cells in the bone marrow. “OPN-6602 represents an exciting and novel therapeutic target that will provide a much-needed option for our relapsed and refractory myeloma patient population,” said principal investigator Dr. Andrew Sochacki. “The innovative approach of this therapy has the potential to significantly improve outcomes for patients who have exhausted other treatment options. This collaboration with Opna underscores our commitment to advancing cutting-edge research and delivering new, effective therapies to patients who need them the most.” Read more about the study: https://lnkd.in/dP7KbtX3 #biotech #cancerresearch #multiplemyeloma

Tubulis GmbH doses first patient in phase 1/2a trial investigating #ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary linker technology with better biophysical properties that demonstrated effective and durable responses in a range of preclinical models. ℹ Read more: https://lnkd.in/gEZhZcaM

Read about our work of applying CAR-T cell membrane coating to chemo-drug-loaded nanoparticles for the treatment of lung cancer. CAR-T technology can help camouflage nanoparticles for improved circulation and targeted delivery. Congratulations to Serkan Yaman Harish Ramachandramoorthy Manoj Sabnani Kytai Nguyen #bioactivematerials #CARTcells #cellmembrane #nanoparticles #nanomedicine #bioengineering

Treatment resistant tumors and 'mixed responses' can be difficult to uncover when solely focusing on a patient's RECIST 1.1 TL Sum of Diameters. We published a TRACERx study in Nature Comms, showing that this type of dissociated, heterogenous radiological response is linked to chromosomal instability through TP53 pathway perturbations. A great #PrecisionMedicine collaboration between academia and pharma which may help to personalise cancer treatment for future patients. Thanks to all involved, especially Sebastijan Hobor, Crispin Hiley, Eva Grönroos, Andy Brown and Charles Swanton

The inability of cells to kill themselves is directly linked to both the development of cancer, and resistance to therapy. The major advances in mapping of cell death-associated signalling pathways that led to venetoclax being approved for use in the clinic – and an explosion of associated clinical trial activity – have now firmly established the pharmacological targeting of cell death pathways, including apoptosis and autophagy, as a crucial therapeutic approach in cancer treatment. Our infographic maps the signalling cascades involved in apoptosis and autophagy – highlighting major targets of drug intervention, highly sought-after therapeutic strategies and ongoing clinical trials. Check out the free infographic to learn more: https://okt.to/BFYwWU #Infographic #CellDeath #apoptosis #CancerResearch #ResearchChemicals

Treating #PancreaticCancer doesn’t need to be about reinventing the wheel. Perhaps simply reusing it will be enough. I found this study by researchers at @Weill Cornell Medicine particularly interesting. By testing around 6000 compounds on pancreatic tumour organoids, they found that perhexiline maleate could suppress tumour growth. Perhexiline is used to treat a number of heart conditions, including angina. However, If future research finds similar results, it could become a powerful tool to fight cancer. To me, this study highlights the importance of exploring new uses for existing treatments. A better treatment option may be right under our noses! #Oncology #CancerTreatment #Perhexiline

First-line treatment with ivonescimab (AK112; SMT112) monotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) monotherapy in patients with locally advanced or metastatic, PD-L1–positive non–small cell lung cancer (NSCLC), meeting the primary end point of the phase 3 HARMONi-2 trial (NCT05499390)OncLive https://lnkd.in/gj-HGWQP

Patient-derived organoids are 3D cell models created in a lab and useful for drug screening and testing. Recently, tumor organoids from patients with colorectal cancer have shown high predictability for treatment outcomes during preclinical testing. These findings were published in Cell Reports Medicine (DOI: 10.1016/j.xcrm.2023.101335). However, growing and maintaining organoids are still challenging and require adjusting and optimizing the conditions. #organoids #drugscreening #preclinicaltesting